Portal de Periódicos da CAPES

Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe

2022; Taylor & Francis; Volume: 60; Issue: 1 Linguagem: Inglês

10.1080/02770903.2021.2025392

1532-4303

Daniel R. Morales, Anna Ostropolets, Lana Yin Hui Lai, Anthony G. Sena, Scott L. DuVall, Marc A. Suchard, Katia Verhamme, Peter Rjinbeek, Joe Posada, Waheed‐Ul‐Rahman Ahmed, Thamer Alshammary, Heba Alghoul, Osaid Alser, Carlos Areia, Clair Blacketer, Edward Burn, Paula Casajust, Seng Chan You, Dalia Dawoud, Asieh Golozar, Menchung Gong, Jitendra Jonnagaddala, Kristine E. Lynch, Michael E. Matheny, Evan Minty, Fredrik Nyberg, Albert Prats‐Uribe, Martina Recalde, Christian Reich, Martijn Scheumie, Karishma Shah, Nigam H. Shah, Lisa M. Schilling, David Vizcaya, Lin Zhang, George Hripcsak, Patrick Ryan, Daniel Prieto‐Alhambra, Talita Durate-Salles, Kristin Kostka,

Chronic Obstructive Pulmonary Disease (COPD) Research

Objective: Large international comparisons describing the clinical characteristics of patients with COVID-19 are limited. The aim of the study was to perform a large-scale descriptive characterization of COVID-19 patients with asthma.Methods: We included nine databases contributing data from January to June 2020 from the US, South Korea (KR), Spain, UK and the Netherlands. We defined two cohorts of COVID-19 patients ('diagnosed' and 'hospitalized') based on COVID-19 disease codes. We followed patients from COVID-19 index date to 30 days or death. We performed descriptive analysis and reported the frequency of characteristics and outcomes in people with asthma defined by codes and prescriptions.Results: The diagnosed and hospitalized cohorts contained 666,933 and 159,552 COVID-19 patients respectively. Exacerbation in people with asthma was recorded in 1.6–8.6% of patients at presentation. Asthma prevalence ranged from 6.2% (95% CI 5.7–6.8) to 18.5% (95% CI 18.2–18.8) in the diagnosed cohort and 5.2% (95% CI 4.0–6.8) to 20.5% (95% CI 18.6–22.6) in the hospitalized cohort. Asthma patients with COVID-19 had high prevalence of comorbidity including hypertension, heart disease, diabetes and obesity. Mortality ranged from 2.1% (95% CI 1.8–2.4) to 16.9% (95% CI 13.8–20.5) and similar or lower compared to COVID-19 patients without asthma. Acute respiratory distress syndrome occurred in 15–30% of hospitalized COVID-19 asthma patients.Conclusion: The prevalence of asthma among COVID-19 patients varies internationally. Asthma patients with COVID-19 have high comorbidity. The prevalence of asthma exacerbation at presentation was low. Whilst mortality was similar among COVID-19 patients with and without asthma, this could be confounded by differences in clinical characteristics. Further research could help identify high-risk asthma patients.KEY MESSAGESAsthma prevalence in COVID-19 patients varied internationally (5.2–20.5%).The prevalence of asthma exacerbation at presentation with COVID-19 in diagnosed and hospitalized patients was low.Comorbidities were common in COVID-19 patients with asthma.Supplemental data for this article is available online at https://doi.org/10.1080/02770903.2021.2025392 .